Accenture Capital Markets

SEPTEMBER 5, 2023

It’s time to dust off the key to the padlock which has, since the run-up to the first phase of the uncleared margin rules in September 2016, been gladly safeguarding the changes required to your margin and collateral management processes and systems.

Book-building 52

Book-building Management Financial Institution Utilities 52

Cooley M&A

JANUARY 25, 2023

2022 drivers and headwinds Choppy access to capital markets and financing to fund ongoing operations Many life sciences companies faced challenges raising money in the capital markets in 2022. Let’s dig in.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JANUARY 24, 2020

According to Cornerstone Research , the number of M&A class action filings increased from 34 in 2015 to 85 in 2016, 198 in 2017, and 182 in 2018. This trend continued in the first half of 2019, but at a slightly slower pace (72 filings in 1H19 compared to 91 in 1H18 and 91 in 2H18).

M&A 40

M&A Mergers and Acquisitions Mergers Business 40

Growth Business

MARCH 1, 2024

For institutional investors, therefore, private equity can offer exposure to fast-growing, high-potential, mid-sized private companies at a comparatively earlier stage of their growth trajectory than is available through the capital markets. What is private equity and how does it work?

Private Equity 59

Private Equity Equities Investment Business 59

Cooley M&A

FEBRUARY 15, 2017

The overall number of M&A deals in 2016 increased by 1% compared to the year before (Thomson Reuters), but this fact did not grab headlines because the dollar value of M&A deals fell by 16%, mostly due to a significant drop in blockbuster deals. Tech was the second busiest M&A industry in 2016 behind energy.

M&A 40

M&A IPO Pharmaceutical Valuation 40

Cooley M&A

JANUARY 20, 2022

19 treatments from Pfizer, Merck and potentially others hitting the market soon , we expect Big Pharma to continue to parlay this cash flow into growth in other areas of strategic focus. A healthy 90 biopharma M&A transactions were announced in 2021 (compared to 69 in 2020 and 70 in 2019, the most transactions since 2016).

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40